A patient treated with ofatumumab for myasthenia gravis in conjunction with systemic lupus erythematosus and thyroid carcinoma

Abstract

Myasthenia gravis (MG) is an autoimmune disease mediated by B cells and is associated with acetylcholine receptor (AChR) and muscle-specific receptor tyrosine kinase (MuSK) antibodies in the postsynaptic membrane at the neuromuscular junction. Anti-CD20 monoclonal antibodies, such as ofatumumab demonstrated promising disease control in MG patients. We presented the rare case of a 34-year-old female with acetylcholine receptor-positive myasthenia gravis (AChR-MG), concomitant with systemic lupus erythematosus (SLE) and metastatic thyroid carcinoma, who was treated with ofatumumab and exhibited improvements during follow-up.

Keywords: anti-CD20 monoclonal antibody; myasthenia gravis; ofatumumab.

Figure 1.

Chest CT. Multiple pulmonary nodules are shown by red arrows.ing intensity of HMW-MAA-positive cells in primary ALM lesions.

Figure 2.

Curves of QMG score and CD19+ B Lymphocyte subsets versus time. The patient was started with ofatumumab on Day 0, then her QMG score (blue curve) and CD19+ B Lymphocyte subsets(orange curve, %) were recorded to Day 180.